艾基奥仑赛治疗复发难治多发性骨髓瘤的健康相关生活质量
KarMMa 2期试验中,128例接受艾基奥仑赛(ide-cel)治疗的患者有126例(98%)纳入健康相关生活质量分析。基线时疾病负担高且显著差于年龄和性别加权的一般人群。治疗后第1个月疼痛和疾病症状、第2个月疲乏、躯体功能、认知功能和总体健康状况/生活质量出现统计学显著且临床有意义的改善,并持续至治疗后15至18个月。
要点
- 艾基奥仑赛治疗后第1个月疼痛和疾病症状即出现临床有意义的改善。
- 疲乏、躯体功能和总体健康状况/生活质量的改善在第2个月出现并持续至15至18个月。
- 基线的健康相关生活质量显著差于年龄和性别加权的一般人群。
核心结论
- 对于预后差且治疗选择有限的三类暴露复发难治多发性骨髓瘤患者,单次艾基奥仑赛输注可提供早期、持续、统计学显著且临床有意义的健康相关生活质量改善。
研究设计与样本
- KarMMa 2期试验(NCT03361748)中评估艾基奥仑赛治疗复发难治多发性骨髓瘤患者健康相关生活质量的分析。
- 128例接受艾基奥仑赛治疗的患者中126例(98%)纳入健康相关生活质量分析。
- 使用欧洲癌症研究与治疗组织生活质量核心30问卷及其补充的20项多发性骨髓瘤模块,以及EuroQol五维度五水平量表,在筛查、基线(淋巴细胞清除前≤72小时或当天)、艾基奥仑赛治疗当天及治疗后进行测评。
主要发现
- 治疗前基线复发难治多发性骨髓瘤负担高,且显著差于年龄和性别加权的一般人群。
- 至第1个月,疼痛较基线改善-8.9,疾病症状较基线改善-10.2,均超过预设的最小重要差异阈值,为统计学显著且临床有意义的改善。
- 至第2个月,疲乏较基线改善-7.2,躯体功能较基线改善6.1,认知功能较基线改善6.7,总体健康状况/生活质量较基线改善8.0,均为统计学显著且临床有意义的改善。
- 疲乏、疼痛和躯体功能的临床有意义改善分别在9个月、12个月和18个月时最为突出,并持续至艾基奥仑赛治疗后15至18个月。
关键数值与推荐
- 最小重要差异预设阈值:基线平均变化超过该阈值视为临床有意义。
- 临床有意义变化比例采用患者内变化阈值评估。
- 稳定改善时间定义为连续≥2次访视出现临床有意义的健康相关生活质量改善,采用Kaplan-Meier法分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class exposed, relapsed and refractory multiple myeloma (RRMM) in the phase 2 KarMMa (Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma) trial. We assessed health-related quality of life (HRQoL) among KarMMa patients. The European Organization for Research and Treatment of Cancer Quality of Life C30 Questionnaire and its supplementary 20-item multiple myeloma module, as well as the EuroQol 5-dimension 5-level instrument, were administered at screening, baseline (≤72 hours before or same day as lymphodepletion), day of ide-cel treatment, and after ide-cel treatment. Mean changes from baseline that exceeded the predetermined threshold of minimally important difference were deemed clinically meaningful. The proportions of patients experiencing clinically meaningful changes in HRQoL were assessed using within-patient change thresholds. Time to stable improvement (≥2 consecutive visits with clinically meaningful HRQoL improvements) was analyzed by using the Kaplan-Meier method. A total of 126 (98%) of 128 patients treated with ide-cel were included in the HRQoL analysis. Pretreatment baseline RRMM burden was high and meaningfully worse than that in the age- and sex-weighted general population. Statistically significant and clinically meaningful improvements from baseline were observed by month 1 for pain (-8.9) and disease symptoms (-10.2), and by month 2 for fatigue (-7.2), physical functioning (6.1), cognitive functioning (6.7), and global health status/QoL (8.0). Clinically meaningful improvements in fatigue, pain, and physical functioning were most prominent at months 9, 12, and 18, respectively, and were sustained through 15 to 18 months after ide-cel treatment. For triple-class exposed patients with RRMM with a poor prognosis and few treatment options, a single ide-cel infusion provides early, sustained, statistically significant, and clinically meaningful improvements in HRQoL. This study was registered at Clinicaltrials.gov as #NCT03361748.
引用
- Delforge M, Shah N, Miguel JSF, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022. PMID: 34933328. doi:10.1182/bloodadvances.2021005913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。